Formulary and support resources
Resources to support you with your decision making and implementation of EYLEA® (aflibercept) 8 mg for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults and the treatment of visual impairment due to diabetic macular oedema (DMO) in adults.
EYLEA 8 mg represents a line extension from the currently available EYLEA 2 mg dose.
An updated statement from NICE here states that “Aflibercept 8 mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2 mg formulation (TA 346 and TA294). Therefore, it would not be an efficient use of NHS resources to conduct an evaluation. Aflibercept 8 mg should therefore be considered for routine commissioning.”
As it is a line extension, implementation of EYLEA 8 mg may differ between local health systems. This page contains resources to support your formulary update activities across a range of likely scenarios.
Click below to view guides based on the EYLEA 8 mg Summary of Product Characteristics (SmPC) and further information to support a formulary application.
All of the information you might require regarding pricing, pack size, storage and ordering can be found below in the PRE-FILLED SYRINGE (PFS) summary table.
Click below to view the EYLEA 8 mg Summary of Product Characteristics (SmPC) and the EYLEA prescriber guide.